What Is P021?

P021, also written P21, Peptide 021, or Compound 021, is a synthetic neurotrophic peptide mimetic derived from a short biologically active region of human ciliary neurotrophic factor (CNTF).

Researchers developed P021 to retain selected neurogenic and neurotrophic actions of CNTF while reducing the poor pharmacokinetics, limited blood–brain barrier penetration, and systemic adverse effects associated with the full-length protein.

🧬 Molecular Structure

🧪 Published sequence notation

Ac-Asp-Gly-Gly-Leu-^AG-NH₂

Common shorthand:

Ac-DGGL^AG-NH₂

What the superscript A means

The notation ^AG denotes a single adamantylated glycine-like noncanonical residue. It should not be interpreted as two standard residues, alanine followed by glycine.

Core CNTF-derived region

The standard amino-acid core is Asp-Gly-Gly-Leu, generally described as corresponding to CNTF residues 148–151, although some papers use slightly shifted residue numbering.

⚛️ Molecular Weight and 🧫 Formula

Because noncanonical-residue notation varies, the molecular formula should be taken from a qualified structural reference and independently confirmed by high-resolution mass spectrometry and NMR rather than copied from a vendor page.

📅 Discovery Timeline and Research History

1990s–2000s: CNTF-derived peptide mapping

Researchers mapped biologically active regions of CNTF and developed shorter peptide mimetics intended to preserve neurotrophic activity.

Peptide 6 developed

An 11-amino-acid CNTF-derived peptide, commonly called peptide 6, was investigated for neurogenesis and cognition.

Peptide 6c identified

The active sequence was reduced to the four-amino-acid DGGL core.

2010: P021 introduced

Researchers added an adamantylated glycine residue to the DGGL peptide to improve stability, lipophilicity, oral bioavailability, and brain penetration. Mouse studies reported improved learning, neurogenesis, and synaptic plasticity.

2014: Aging and Alzheimer’s-model studies

Chronic oral treatment was reported to improve cognition and reduce abnormal tau phosphorylation in aged and transgenic mice.

2016: Mechanistic review

P021 was summarized as a CNTF-derived neurogenic compound acting through LIF inhibition, BDNF enhancement, and reduced GSK3β activity.

2017: Down syndrome and early Alzheimer’s-model studies

Prenatal and early-postnatal treatment improved selected developmental, synaptic, and cognitive outcomes in Ts65Dn and 3×Tg-AD mice.

2019: Retinal disease model

P021 reduced selected AMD-like retinal pathology in mice.

2020–2021: Prenatal and postnatal prevention studies

Early treatment in 3×Tg-AD mice reduced later synaptic deficits, cognitive impairment, tau pathology, and amyloid burden.

2024: CDKL5 deficiency research

P021 improved neuronal proliferation and maturation deficits in vitro but produced limited benefit in Cdkl5-knockout mice.

2026: MRI microstructure research

Preclinical imaging work continued to examine brain changes associated with early P021 treatment in Alzheimer’s models.

Relationship to CNTF and Peptide 6

What CNTF does

Ciliary neurotrophic factor supports survival and differentiation of selected neurons and glial cells. It signals through a receptor complex involving CNTFRα, LIFRβ, and gp130, activating JAK/STAT and other pathways.

Limitations of full-length CNTF

• Poor blood–brain barrier penetration
• Short systemic half-life
• Large protein size
• Potential systemic inflammatory or metabolic effects
• Immunogenicity concerns

Peptide 6

Peptide 6 is an 11-amino-acid CNTF-derived peptide that demonstrated neurogenic effects but retained less favorable pharmacokinetic properties.

Peptide 6c

Peptide 6c is the acetylated and amidated DGGL tetrapeptide core.

P021 optimization

The adamantylated residue was added to the C-terminus to create a smaller, more lipophilic, orally active experimental compound.

🧠 Proposed Mechanism of Action

1. LIF pathway inhibition

P021 has been described as reducing leukemia inhibitory factor signaling. LIF can suppress adult hippocampal neurogenesis under selected conditions.

2. BDNF enhancement

Multiple animal studies report increased BDNF expression after P021 treatment, although this effect was not reproduced in every disease model.

3. GSK3β regulation

Increased inhibitory phosphorylation of GSK3β is proposed to reduce tau phosphorylation and support neuronal survival.

4. CREB signaling

Studies report improved phosphorylated CREB, a transcription factor involved in memory, neuronal survival, and synaptic plasticity.

5. Synaptic-protein restoration

P021 has been associated with restoration of synaptophysin, synapsin, PSD-95, GluR1, NR1, and MAP2 in selected mouse models.

🎯 Receptor and Pathway Profile

Neurogenesis and Brain-Plasticity Research

Adult dentate gyrus

P021 has been studied extensively in the hippocampal dentate gyrus, a region associated with adult neurogenesis and memory.

Proliferation and neuronal maturation

Animal studies report increases in Ki-67-positive proliferating cells and doublecortin-positive immature neurons.

Survival of newborn neurons

BDNF-related signaling may improve survival and integration of newly generated cells.

Not universal across models

The 2024 CDKL5-deficiency study found strong in-vitro effects but limited in-vivo benefit, demonstrating that disease context matters.

No proof of human neurogenesis

No human imaging, histological, cerebrospinal-fluid, or clinical study has established increased neurogenesis after P021.

Memory and Cognitive Research

Normal adult mice

Early P021 studies reported better learning and memory performance in normal mice.

Aged rats and mice

Treatment improved selected cognitive tasks and reduced age-related neurogenic deficits.

3×Tg-AD mice

Long-term dietary treatment improved or prevented deficits in Morris water maze and related memory tests.

Ts65Dn Down syndrome model

Prenatal and early-postnatal treatment improved developmental milestones and later hippocampal memory performance.

Human evidence

No controlled human cognition trial has been published.

Tau, GSK3β, and Tauopathy Research

Tau hyperphosphorylation

Excessive tau phosphorylation contributes to microtubule dysfunction, aggregation, neurofibrillary pathology, and neuronal injury.

GSK3β as a tau kinase

GSK3β phosphorylates tau at multiple sites associated with Alzheimer’s pathology.

P021 findings

Studies report increased inhibitory phosphorylation of GSK3β and reduced tau hyperphosphorylation in transgenic mouse models.

Timing of treatment

Several of the strongest studies began treatment before extensive pathology, which is more consistent with prevention than reversal of established human disease.

No proven human tau therapy

P021 has not been shown to reduce tau PET signal, cerebrospinal-fluid tau, dementia progression, or clinical disability in humans.

Amyloid and Alzheimer’s-Model Research

3×Tg-AD model

This mouse model develops amyloid and tau abnormalities along with synaptic and cognitive deficits.

Long-term prevention studies

P021 treatment beginning before overt pathology reduced later amyloid burden, tau pathology, synaptic loss, and cognitive impairment.

Chronic oral treatment

Dietary delivery over many months was used in several studies, supporting oral activity in rodents.

Model limitations

Mouse amyloid and tau models reproduce only parts of sporadic human Alzheimer’s disease.

No human disease-modifying evidence

No phase 1, 2, or 3 trial has established safety or efficacy in Alzheimer’s disease.

Dendritic and Synaptic Research

Dendritic markers

P021 increased or preserved MAP2 expression and dendritic architecture in selected models.

Presynaptic markers

Synaptophysin and synapsin-1 deficits were improved in several studies.

Postsynaptic markers

PSD-95, GluR1, and NMDA-receptor subunit NR1 were restored or preserved.

CREB and plasticity

Improved CREB activity provides a plausible link between neurotrophic signaling and memory-associated gene expression.

Synaptic markers are not functional proof alone

Protein-expression changes require correlation with electrophysiology, behavior, and durable clinical outcomes.

Down Syndrome and Developmental Research

Ts65Dn mouse model

Ts65Dn mice model selected features of Down syndrome, including developmental delay, hippocampal dysfunction, and Alzheimer-like changes.

Prenatal and early-postnatal treatment

P021 improved selected developmental milestones, synaptic proteins, recognition memory, and spatial learning.

Translational limitations

Prenatal neurotrophic manipulation raises major safety questions involving fetal development, cell proliferation, circuit formation, and long-term effects.

No human prenatal use

P021 has not been established as safe or effective during human pregnancy, infancy, or childhood.

CDKL5 Deficiency Research

Human neuronal-cell model

In 2024, P021 improved neuronal proliferation, survival, maturation, and GSK3β-related abnormalities in CDKL5-deficient SH-SY5Y cells.

Mouse findings

Chronic treatment in young and adult Cdkl5-knockout mice failed to increase BDNF or correct major neuroanatomical abnormalities and produced only limited behavioral benefit.

Why this matters

The study demonstrates that successful cell-culture findings may not translate to whole-animal efficacy.

No clinical evidence

P021 has not been tested as an established treatment for CDKL5 deficiency disorder in humans.

Retinal and AMD-Like Research

AMD-like mouse model

A 2019 study examined P021 in an amyloid-associated retinal-degeneration model.

Reported effects

P021 reduced selected AMD-like pathology, retinal inflammation, and degeneration-related changes.

Possible shared mechanisms

BDNF signaling, GSK3β regulation, amyloid biology, inflammation, and neuronal survival may be relevant to both brain and retinal tissue.

No human ophthalmic indication

P021 is not approved for age-related macular degeneration, diabetic retinopathy, glaucoma, or inherited retinal disease.

Oral Availability and Brain Exposure

Purpose of adamantane modification

The adamantylated glycine residue was added to increase lipophilicity and resistance to degradation.

Rodent oral administration

Multiple studies delivered P021 in food and reported central nervous system effects, supporting oral activity in animals.

Blood–brain barrier claims

Published reviews describe P021 as blood–brain barrier permeable and possessing pharmacokinetics suitable for oral treatment.

Missing human data

Human oral bioavailability, plasma half-life, metabolite profile, brain concentration, food effects, and dose proportionality are unknown.

Small molecular weight is not sufficient

Brain entry depends on polarity, hydrogen bonding, efflux transport, protein binding, metabolism, and formulation—not mass alone.

Evidence Limitations and Clinical Interpretation

Preclinical evidence only

P021 has a stronger animal evidence base than many commercial research peptides, but it still lacks established human trials.

Research-group concentration

Many studies come from a connected group of investigators and related Alzheimer’s-model programs.

Preventive treatment designs

Some studies began during prenatal life, early postnatal development, or before overt pathology.

Model-specific failures

The CDKL5 study found limited in-vivo efficacy despite positive cell results.

Potential publication bias

Positive animal studies may be more likely to be published than neutral results.

No established therapeutic window

The dose range that separates benefit from abnormal proliferation or other adverse effects is unknown in humans.

Safety and Regulatory Considerations

Animal tolerability

Published studies generally did not report severe toxicity, major weight loss, or obvious behavioral impairment at tested doses.

Insufficient toxicology

Comprehensive genotoxicity, carcinogenicity, reproductive, developmental, immunotoxic, cardiac, and chronic-organ toxicity packages are not publicly established.

Developmental exposure risk

Prenatal or neonatal promotion of neurogenesis and growth-factor signaling could produce unintended changes in circuit formation or tumor biology.

BDNF and proliferation concerns

Increasing neurotrophic signaling is not universally beneficial and may have disease-, region-, and dose-dependent consequences.

Adamantane-related pharmacology

The hydrophobic residue may alter tissue retention, solubility, off-target binding, and metabolite formation.

Regulatory status

P021 is not FDA approved and has no recognized approved indication.

🧪 Laboratory Testing Methods

📄 How to Interpret a P021 COA

1. Verify the exact notation: Ac-DGGL^AG-NH₂.
2. Confirm that ^AG is one noncanonical adamantylated glycine residue: It is not ordinary Ala-Gly.
3. Require a complete structural drawing: Shorthand alone is insufficient.
4. Confirm N-terminal acetylation and C-terminal amidation.
5. Confirm intact molecular weight: Approximately 578.3 g/mol for the published reference compound.
6. Use MS/MS and NMR: HPLC purity alone cannot verify the adamantane linkage.
7. Measure net peptide content: Area purity is not the labeled milligram amount.
8. Review parent DGGL peptide, deletion sequences, free modifier, water, counterions, and residual solvents.
9. Match microbiological testing to route: Oral, injectable, and nasal products require different controls.
10. Do not infer efficacy: A COA cannot prove neurogenesis, memory improvement, tau reduction, Alzheimer’s prevention, or brain penetration.

📊 P021 vs Peptide 6 vs Peptide 6c vs CNTF

P021 vs Dihexa vs FGL vs DNSP-11

P021 vs Approved Alzheimer’s Treatments

P021 vs p21/CDKN1A

🔗 Related Peptides and Pathways

• CNTF: Parent neurotrophic protein.
• Peptide 6: Longer CNTF-derived neurogenic peptide.
• Peptide 6c: Ac-DGGL-NH₂ parent tetrapeptide.
• BDNF: Neurotrophic factor increased in several P021 studies.
• LIF: Cytokine pathway proposed to be inhibited by P021.
• GSK3β: Tau kinase whose activity is reduced in several models.
• CREB: Memory- and plasticity-related transcription factor.
• Adamantylated glycine: Noncanonical residue used to improve pharmacokinetic properties.

🖼️ Original Diagram Specifications

Diagram 1: P021 molecular structure

Show N-acetyl-DGGL linked to one adamantylated glycine residue with a C-terminal amide. Clearly label the noncanonical residue.

Diagram 2: CNTF-to-P021 development

Show full-length CNTF → peptide 6 → DGGL peptide 6c → adamantane-modified P021.

Diagram 3: LIF–BDNF–GSK3β pathway

Show P021 reducing LIF signaling, increasing BDNF, activating downstream neurotrophic pathways, inhibiting GSK3β, and reducing tau phosphorylation.

Diagram 4: Neurogenesis pathway

Show dentate-gyrus progenitor proliferation, doublecortin-positive immature neurons, maturation, survival, and synaptic integration.

Diagram 5: Alzheimer’s-model outcomes

Show tau, amyloid, synaptic proteins, CREB, neurogenesis, inflammation, and cognition as separate preclinical endpoints.

Diagram 6: Evidence ladder

Show chemical identity, cell studies, rodent PK, mouse disease models, formal toxicology, phase 1 trials, phase 2/3 trials, and regulatory approval.

Diagram 7: COA workflow

Show structural drawing, HRMS, MS/MS, NMR, chiral analysis, parent peptide, adamantane impurities, net content, microbiology, and stability.

❓ Frequently Asked Questions

Is P021 a peptide?

It is a synthetic peptidergic compound containing a CNTF-derived tetrapeptide core and a noncanonical adamantylated glycine residue.

What is the correct sequence?

Ac-DGGL^AG-NH₂.

Does AG mean alanine-glycine?

No. The superscript notation represents one adamantylated glycine residue.

What is its molecular weight?

Published studies report approximately 578.3 g/mol.

Is P021 the same as p21?

No. p21/CDKN1A is a cell-cycle protein.

Is P021 FDA approved?

No.

Does P021 cross the blood–brain barrier?

Rodent research and reviews describe it as BBB permeable, but human brain exposure is unknown.

Is P021 orally active?

Yes in multiple rodent studies, including long-term dietary administration.

Does it increase BDNF?

Several models show increased BDNF, but the effect was absent in one recent CDKL5 mouse study.

Does P021 improve memory?

It improved cognition in multiple animal models. No human trial has established memory benefit.

Does it reduce tau?

Animal studies report reduced abnormal tau phosphorylation and accumulation.

Does it treat Alzheimer’s disease?

No human efficacy has been established.

Is P021 safe?

Animal studies generally report good tolerability, but complete human safety and chronic toxicology are unknown.

Does 99% HPLC purity prove authentic P021?

No. The adamantylated residue, linkage, sequence, termini, exact mass, and net content require orthogonal confirmation.

Final Thoughts

P021 is a legitimate published experimental compound with a clearer identity and stronger preclinical evidence base than many designer peptides. It is derived from the DGGL active region of CNTF and modified with N-terminal acetylation, C-terminal amidation, and one adamantylated glycine residue.

Animal studies report neurogenesis, synaptic preservation, improved cognition, increased BDNF and CREB signaling, reduced GSK3β activity, and lower tau and amyloid pathology in selected models. However, the evidence remains preclinical, treatment often began before advanced disease, and the 2024 CDKL5 study showed limited in-vivo benefit despite positive cell findings.

Legitimate P021 material should be verified for the complete noncanonical structure, exact mass, DGGL sequence, acetylation, amidation, adamantane linkage, stereochemistry, parent-peptide and modifier impurities, net content, route-specific microbiological quality, and stability.

📚 References

1. Blanchard J, et al. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Letters. 2010.
2. Li B, et al. Neurotrophic peptide P021 and neurogenesis in adult animals. FEBS Letters. 2010.
3. Bolognin S, et al. Rescue of cognitive aging by administration of a neurogenic and/or neurotrophic compound. Neurobiology of Aging. 2014.
4. Kazim SF, et al. Disease-modifying effect of chronic oral treatment with a CNTF-derived peptidergic compound in a triple-transgenic mouse model of Alzheimer’s disease. Neurobiology of Disease. 2014.
5. Kazim SF, et al. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair. Molecular Neurodegeneration. 2016.
6. Kazim SF, et al. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer-like memory deficits in the Ts65Dn mouse model of Down syndrome. Scientific Reports. 2017.
7. Baazaoui N, et al. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimer’s Research & Therapy. 2017.
8. Liu Y, et al. Inhibition of AMD-like pathology with a neurotrophic compound. 2019.
9. Wei W, et al. Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology. 2020.
10. Wei W, et al. Neurotrophic treatment initiated during early postnatal development prevents Alzheimer-like behavior and synaptic dysfunction. 2021.
11. Gascon S, et al. Peptides derived from growth factors to treat Alzheimer’s disease. 2021.
12. Mottolese N, et al. Effects of a CNTF small-molecule mimetic in CDKL5 deficiency models. 2024.
13. Falangola MF, et al. Diffusion MRI measures detect brain microstructure changes due to early P021 treatment. 2026.
14. US Patent. Neurotrophic peptides for treatment of tauopathies.
15. Pasquin S, Sharma M, Gauchat JF. Ciliary neurotrophic factor (CNTF): new facets of an old molecule for treating neurodegenerative and metabolic syndrome pathologies. Cytokine & Growth Factor Reviews.
16. Ip NY, et al. The alpha component of the CNTF receptor is required for signaling. Cell.
17. Davis S, et al. Released form of CNTF receptor potentiates CNTF signaling. Science.
18. Stahl N, et al. Association and activation of Jak-Tyk kinases by CNTF receptor components. Science.
19. Bonni A, et al. Cell survival promoted by the Ras-MAPK signaling pathway. Science.
20. Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nature Reviews Neuroscience.
21. Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handbook of Experimental Pharmacology.
22. Waterhouse EG, Xu B. New insights into the role of BDNF in synaptic plasticity. Molecular and Cellular Neuroscience.
23. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. Journal of Cell Science.
24. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. Journal of Neurochemistry.
25. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends in Molecular Medicine.
26. Wang Y, Mandelkow E. Tau in physiology and pathology. Nature Reviews Neuroscience.
27. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease. Science.
28. Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell.
29. Oakley H, et al. Intraneuronal beta-amyloid aggregates and cognitive deficits in transgenic mice. Journal of Neuroscience.
30. Oddo S, et al. Triple-transgenic model of Alzheimer’s disease. Neuron.
31. Deng W, Aimone JB, Gage FH. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nature Reviews Neuroscience.
32. Gonçalves JT, Schafer ST, Gage FH. Adult neurogenesis in the hippocampus. Cell.
33. Kempermann G, et al. Human adult neurogenesis: evidence and remaining questions. Cell Stem Cell.
34. Ben-Ari Y. Excitatory actions of GABA during development. Nature Reviews Neuroscience.
35. Herault Y, et al. Rodent models in Down syndrome research. Disease Models & Mechanisms.
36. Dierssen M. Down syndrome: the brain in trisomic mode. Nature Reviews Neuroscience.
37. Fehr S, et al. The CDKL5 disorder is an independent clinical entity. European Journal of Human Genetics.
38. Olson HE, et al. Cyclin-dependent kinase-like 5 deficiency disorder. Pediatric Neurology.
39. Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chemical Reviews.
40. Liu J, et al. The many faces of the adamantyl group in drug design. European Journal of Medicinal Chemistry.
41. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives and current development trends. Bioorganic & Medicinal Chemistry.
42. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today.
43. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chemical Biology & Drug Design.
44. International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures.
45. International Council for Harmonisation. ICH Q3A and Q3B: Impurities in New Drug Substances and Products.
46. International Council for Harmonisation. ICH Q3C: Residual Solvents.
47. International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products.
48. International Council for Harmonisation. ICH M10: Bioanalytical Method Validation.
49. United States Pharmacopeia General Chapter <621>: Chromatography.
50. United States Pharmacopeia General Chapter <71>: Sterility Tests.
51. United States Pharmacopeia General Chapter <85>: Bacterial Endotoxins Test.
52. United States Pharmacopeia General Chapters <232> and <233>: Elemental Impurities.

Identity, molecular structure, CNTF relationship, neurogenesis, cognition, tau, amyloid, developmental, retinal, pharmacokinetic, safety, and analytical evidence were reviewed in July 2026. P021 remains an unapproved investigational compound.